Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409539 · ClinicalTrials.gov registry record · Phase 2
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 550
- Enrollment target
NCT00409539 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 550 participants.
The verdict
NCT00409539, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 550 participants
- Enrollment target
Study Summary
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The hypothesis will be tested by measuring the change in mean voids/24 hrs after treatment with SMP-986 compared to placebo, as well comparing the change in: the severity of urgency episodes, mean number of urgency episodes/24 hr, mean number of incontinence episodes/24 hr and the mean void volume/void between SMP-986 and placebo.
Interventions
- DRUG Placebo
- DRUG SMP-986
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409539
The ClinicalTrials.gov registry entry for NCT00409539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00409539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00409539 about?
NCT00409539 is a clinical study titled "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)". SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The hypothesis will be tested by measu...
What is the current status of trial NCT00409539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 550 participants. The study started on 2006-12. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00409539?
The interventions under investigation include: Placebo (DRUG), SMP-986 (DRUG).
Who is sponsoring clinical trial NCT00409539?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.